Open Access Articles- Top Results for Zoledronic acid

Zoledronic acid

Zoledronic acid
Systematic (IUPAC) name
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
Clinical data
AHFS/ monograph
MedlinePlus a605023
Licence data EMA:Link, US FDA:link
  • ℞-only (U.S.)
Pharmacokinetic data
Protein binding 22%
Metabolism Nil
Half-life 146 hours
Excretion Renal (partial)
PubChem CID 68740
DrugBank DB00399
ChemSpider 61986
UNII 70HZ18PH24 7pxY
KEGG D08689 7pxN
Chemical data
Formula C5H10N2O7P2
272.09 g/mol
 14pxN (what is this?)  (verify)

Zoledronic acid (INN) or zoledronate (marketed by Novartis under the trade names Zometa, Zomera, Aclasta and Reclast) is a bisphosphonate given intravenously.

Mechanism of Action

Zoledronic acid slows down bone resorption, allowing the bone-forming cells time to rebuild normal bone and allowing bone remodeling.[1]

Approvals and indications

In all cases administration is by intravenous infusion over a minimum of 5 minutes.

Bone complications of cancer

Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis.[2] It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.[3]

It can be administered at home rather than in hospital. Such administration has shown safety and quality-of-life benefits in breast cancer patients with bone metastases.[4]


Marketed as Aclasta (in Australia) or Reclast (in the US), zoledronic acid may be given as a 5 mg infusion once per year for treatment of osteoporosis in men and post-menopausal women at increased risk of fracture.[medical citation needed]

In 2007, the U.S. Food and Drug Administration (FDA) also approved Reclast for the treatment of postmenopausal osteoporosis.[medical citation needed]

Pagets disease

As Reclast a single dose of 5 mg is used for the treatment of Paget's disease.[medical citation needed]

Side effects

Side effects can include fatigue, anemia, muscle aches, fever, and/or swelling in the feet or legs. Flu-like symptoms are commonly experienced after the first zoledronate infusion, although not subsequent infusions, and are thought to occur because of its potential to activate human γδ T cells (gamma/delta T cells).

Risk of severe renal impairment. Appropriate hydration is important prior to administration & adequate calcium and vitamin D intake prior to Aclasta therapy in patients with preexisting hypocalcaemia, and for 10 days following Aclasta in patients with Paget's disease of the bone. Monitor for other mineral metabolism disorders; avoid invasive dental procedures for those who develop osteonecrosis of the jaw.[5]

Zoledronate is rapidly processed via the kidneys; consequently its administration is not recommended for patients with reduced renal function or kidney disease.[6] Some cases of acute renal failure requiring dialysis or having a fatal outcome, following Reclast use, have been reported to the U.S. Food and Drug Administration (FDA).[7] This assessment was confirmed by the European Medicines Agency (EMA) whose Committee for Medicinal Products for Human Use (CHMP) adopted new contraindications for the medication on 15 December 2011, including those with hypocalcaemia and severe renal impairment with creatinine clearance of less than 35 ml/min.[8]

A rare complication that has been recently observed in cancer patients being treated with bisphosphonates is osteonecrosis of the jaw. This has mainly been seen in patients with multiple myeloma treated with zoledronate who have had dental extractions.[9]

After approving the drug on 8 July 2009, the European Medicines Agency conducted a class review of all bisphosphonates, including Zoledronate, after several cases of atypical fractures were reported.[10] In 2008, the EMA's Pharmacovigilance Working Party (PhVWP) noted that alendronic acid was associated with an increased risk of atypical fracture of the femur that developed with low or no trauma. In April 2010, the PhVWP noted that further data from both the published literature and post-marketing reports were now available that suggested that atypical stress fractures of the femur may be a class effect. The European Medicines Agency then reviewed all case reports of stress fractures in patients treated with bisphosphonates, relevant data from the published literature and data provided by the companies that market bisphosphonates. The Agency recommended that doctors who prescribe bisphosphonate-containing medicines should be aware that atypical fractures may occur rarely in the femur, especially after long term use and that doctors who are prescribing these medicines for the prevention or treatment of osteoporosis should regularly review the need for continued treatment, especially after five or more years of use.[10]


Zoledronic acid has been found to have a direct antitumour effect and to synergistically augment the effects of other antitumor agents in osteosarcoma cells.[11]

Zoledronate has shown significant benefits versus placebo over three years, with a reduced number of vertebral fractures and improved markers of bone density.[12][13] An annual dose of zoledronic acid may also prevent recurring fractures in patients with a previous hip fracture.[14]

With hormone therapy for breast cancer

An increase in Disease-Free Survival (DFS) was found in the ABCSG-12 trial, in which 1,803 premenopausal women with endocrine-responsive early breast cancer received anastrozole with zoledronic acid.[15] A retrospective analysis of the AZURE trial data revealed a DFS survival advantage, particularly where estrogen had been reduced.[16]

In a meta-analysis of trials where upfront zoledronic acid was given to prevent aromatase inhibitor-associated bone loss, active cancer recurrence appeared to be reduced.[17] The results of clinical studies of adjuvant treatment on early-stage hormone-receptor-positive breast-cancer patients under hormonal treatment - especially with the bisphosphonate zoledronic acid - caused excitement because they demonstrated an additive effect on decreasing disease relapses at bone or other sites. A number of clinical and in vitro and in vivo preclinical studies, which are either ongoing or have just ended, are investigating the mechanisms and antitumoral activity of bisphosphonates.[18] Ongoing large trials testing bisphosphonates as adjuvant treatment of breast cancer include NSABP B-34,[19] the NATAN trial,[20] and SWOG-S0307.[21] A 2010 review concluded that "adding zoledronic acid 4 mg intravenously every 6 months to endocrine therapy in premenopausal women with hormone receptor-positive early breast cancer ... is cost-effective from a US health care system perspective."[22]


  • Poor renal function (e.g. CrCl<30 mL/min)[23]
  • Hypocalcemia
  • Pregnancy
  • Paralysis


  1. ^ Aclasta label- Australia
  2. ^ National Prescribing Service (2009). "Zoledronic Acid for Osteoporosis". Medicines Update, Available at
  3. ^ Zomera prescribing information
  4. ^ PMID 15870721 Wardley, Davidson Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005 May 23; 92(10): 1869–1876. Published online 2005 May 3. doi:10.1038/sj.bjc.6602551. Free Full Text
  5. ^
  6. ^
  7. ^
  8. ^
  9. ^ Durie BG, Katz M, Crowley J (2005). "Osteonecrosis of the jaw and bisphosphonates". N. Engl. J. Med. 353 (1): 99–102; discussion 99–102. PMID 16000365. doi:10.1056/NEJM200507073530120. 
  10. ^ a b
  11. ^ Koto K, Murata H, Kimura S et al. (July 2010). "Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents". Oncol. Rep. 24 (1): 233–9. PMID 20514467. doi:10.3892/or_00000851. 
  12. ^ Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002). "Intravenous zoledronic acid in postmenopausal women with low bone mineral density". N. Engl. J. Med. 346 (9): 653–61. PMID 11870242. doi:10.1056/NEJMoa011807. 
  13. ^ Black et al.. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM 2007;356;18;1809-1822. Abstract
  14. ^ Lyles K et al. (2007). "Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture". N. Engl. J. Med. 357 (18): 1799–809. PMID 17878149. doi:10.1056/NEJMoa074941. 
  15. ^ PMID 19213681 Gnant, Mlineritsch. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-691 February 12, 2009 Full Free Text [1]
  16. ^ Coleman RE, Winter MC, Cameron D et al. (March 2010). "The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer". Br. J. Cancer 102 (7): 1099–105. PMC 2853093. PMID 20234364. doi:10.1038/sj.bjc.6605604. 
  17. ^ Brufsky A, Bundred N, Coleman R et al. (May 2008). "Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole". Oncologist 13 (5): 503–14. PMC 1069061. PMID 18515735. doi:10.1634/theoncologist.2007-0206. 
  18. ^ Tonyali O, Arslan C, Altundag K (November 2010). "The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives". Expert Opin Pharmacother 11 (16): 2715–25. PMID 20977404. doi:10.1517/14656566.2010.523699. 
  19. ^ Brufsky A, Bundred N, Coleman R et al. (May 2008). "Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole". Oncologist 13 (5): 503–14. PMC 1069061. PMID 18515735. doi:10.1634/theoncologist.2007-0206. 
  20. ^ Phase III Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy (NATAN)
  21. ^
  22. ^ Delea TE, Taneja C, Sofrygin O, Kaura S, Gnant M (August 2010). "Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer". Clin. Breast Cancer 10 (4): 267–74. PMID 20705558. doi:10.3816/CBC.2010.n.034. 
  23. ^ Vondracek, S. F. (2010). "Managing osteoporosis in postmenopausal women". American Journal of Health-System Pharmacy 67 (7 Suppl 3): S9–19. PMID 20332498. doi:10.2146/ajhp100076. 

External links